Clinical Trials Browser

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT03387553 2026-02-09

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Phase EARLY_PHASE1 Active not recruiting

31 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT07254858 2025-11-28

CISN-L

Phase 2 Not yet recruiting

302 enrolled

Breast

Breast Neoplasms

NCT02276443 2025-08-01

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

Phase NA Active not recruiting

798 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06130826 2025-05-30

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

Phase 1 Recruiting

24 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT06908668 2025-04-03

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Phase 2 Not yet recruiting

170 enrolled

Breast

HER2-Negative Locally Advanced Breast Cancer

NCT06691594 2025-02-20

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Phase 2 Not yet recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06084676 2024-07-17

Organoid Model Predictive of Response to Immunotherapies

Terminated

1 enrolled

Breast

Breast Neoplasms

NCT04638751 2024-04-05

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

Recruiting

5,000 enrolled

BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04435964 2023-03-24

G-DEFINER

Completed

247 enrolled

BreastDermatologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Urogenital Neoplasms

NCT02539017 2016-08-10

The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

Clinical Trials

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

CISN-L

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Organoid Model Predictive of Response to Immunotherapies

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

G-DEFINER

The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer